CoChat

Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1

Oumata, Nassima, Bettayeb, Karima, Ferandin, Yoan, Demange, Luc, Lopez-Giral, Angela, Goddard, Marie-Lorène, Myrianthopoulos, Vassilios, Mikros, Emmanuel, Flajolet, Marc, Greengard, Paul, Meijer, Laurent, Galons, Hervé · 2008 · Journal of Medicinal Chemistry

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-beta peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC 50: 220 nM), CDK5/p25 (IC 50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1delta provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-beta in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.

Overview

Integrity signals

Registry

Crossref · 10.1021/jm800109e

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 54 references

Research works printed but not linked: 6

  1. Manning G., 2002, Science, 298, 1933
  2. Meijer L., 2003, Acc. Chem. Res., 36, 417, 10.1021/ar0201198 · doi:10.1021/ar0201198
  3. Meijer L., 2006, CDK Inhibitors and their Potential as Antitumor Agents, 2, 187
  4. Menn B., 2008, Ann. Neurol.
  5. Rockenstein E., 2007, J. Neurosci., 27, 1981, 10.1523/JNEUROSCI.4321-06.2007 · DOI · Paper page
  6. Bettayeb K., 2008, Oncogene

Cited by

Metadata

Authors
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., Meijer, L., & Galons, H.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Laboratoire de Chimie Organique 2, INSERM U 648, Université Paris-Descartes, 4 avenue de l’Observatoire, 75270 Paris cedex 06, France, CNRS, Protein Phosphorylation & Human Disease Group, Station Biologique, B.P. 74, 29682 Roscoff cedex, Bretagne, France, Department of Pharmacy, University of Athens, GR-15771 Athens, Greece, Laboratory of Molecular & Cellular Neuroscience, The Rockefeller University, 1230 York Avenue, New York, New York 10065-6399
Corresponding author
  • Meijer, Laurent
  • Galons, Hervé
Venue
Journal of Medicinal Chemistry
Published
2008-08-13
Volume
51
Issue
17
Pages
5229-5242
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W1989404928
Cited by
139
References
54
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 10 · 2016: 7 · 2015: 5 · 2014: 5 · 2013: 12 · 2012: 12
FWCI
8.15
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
National Institute on Aging (AG09464, P01AG009464)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
cyclin-dependent kinases, casein kinase 1, Alzheimer's disease, amyloid-beta production, tau hyperphosphorylation, CDK1/cyclin B, CDK5/p25, antiproliferative activity, kinase inhibitors
MeSH terms
Roscovitine, Animals, Binding Sites, Cell Line, Humans, Models, Molecular, Purines, Structure-Activity Relationship, Amyloid beta-Peptides, Cyclin-Dependent Kinases, Inhibitory Concentration 50, Casein Kinase I, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.